

# Ahmed O Kaseb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6936806/publications.pdf>

Version: 2024-02-01

81  
papers

8,780  
citations

136740

32  
h-index

69108

77  
g-index

81  
all docs

81  
docs citations

81  
times ranked

9333  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278.	5.0	86
2	Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. Journal of the American Statistical Association, 2022, 117, 533-546.	1.8	6
3	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 862-873.	1.8	568
4	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760.	1.7	20
5	Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Frontiers in Pharmacology, 2022, 13, 848676.	1.6	6
6	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	1.7	44
7	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 1901.	1.7	15
8	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens, 2022, 11, 551.	1.2	8
9	Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 1008-1015.	1.0	10
10	Systemic therapy of liver cancer. Advances in Cancer Research, 2021, 149, 257-294.	1.9	44
11	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311.	1.4	19
12	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 57-69.	1.8	21
13	The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens, 2021, 10, 379.	1.2	16
14	Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021, 12, 756-766.	0.8	2
15	Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients, 2021, 13, 2011.	1.7	8
16	Dietary Nitro Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study. Hepatology, 2021, 74, 3161-3173.	3.6	10
17	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1195-1207.	1.8	19
18	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43

#	ARTICLE	IF	CITATIONS
19	Association of dietary fat intake and hepatocellular carcinoma among US adults. <i>Cancer Medicine</i> , 2021, 10, 7308-7319.	1.3	6
20	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
21	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. <i>OncoImmunology</i> , 2021, 10, 1943253.	2.1	20
22	Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. <i>World Journal of Gastroenterology</i> , 2021, 27, 8166-8181.	1.4	1
23	Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma?. <i>Hpb</i> , 2020, 22, 545-552.	0.1	4
24	Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. <i>Oncology</i> , 2020, 98, 836-846.	0.9	6
25	&lt;p&gt;Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 117-131.	1.8	15
26	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
27	Planning dosimetry for <sup>90</sup> Y radioembolization with glass microspheres: Evaluating the fidelity of <sup>99m</sup> Tc-MAA and partition model predictions. <i>Medical Physics</i> , 2020, 47, 5333-5342.	1.6	25
28	&lt;p&gt;Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 143-153.	1.8	3
29	&lt;p&gt;Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 77-89.	1.8	44
30	Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. <i>Clinical Cancer Research</i> , 2020, 26, 3979-3989.	3.2	184
31	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
32	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
33	Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	4
34	Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. <i>Oncotarget</i> , 2020, 11, 1186-1201.	0.8	27
35	Dual inhibition of IGF-1R and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 80.	6.9	11
36	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	3.2	54

#	ARTICLE	IF	CITATIONS
37	A Machine Learning Model to Predict Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization. <i>Radiology: Artificial Intelligence</i> , 2019, 1, e180021.	3.0	76
38	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	3.4	335
39	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.3	37
40	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
41	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. <i>Journal of Clinical Investigation</i> , 2019, 129, 3324-3338.	3.9	209
42	Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 337-348.	3.7	189
43	Anti-angiogenic therapy in the setting of TACE: an elusive synergy?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 5-6.	3.7	2
44	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	1.3	23
45	Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 451-461.	0.4	76
46	Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 61-73.	1.8	155
47	Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 1817-1827.	2.0	68
48	Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1791-1799.	2.4	76
49	Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 969-978.	3.3	9
50	Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. <i>Clinical and Translational Radiation Oncology</i> , 2017, 4, 39-45.	0.9	11
51	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1403-1412.	1.0	5
52	Type I insulin-like growth factor receptor signaling in hematological malignancies. <i>Oncotarget</i> , 2017, 8, 1814-1844.	0.8	39
53	Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. <i>Journal of Hepatocellular Carcinoma</i> , 2016, 3, 19.	1.8	12
54	Minimally invasive image-guided therapies for hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2016, Volume 3, 55-61.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 773.	1.0	21
56	Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1725-1731.	0.9	43
57	Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 219-226.	0.8	242
58	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
59	Reply. <i>Gastroenterology</i> , 2015, 149, 1643-1644.	0.6	0
60	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	6.9	191
61	Welcome to <i>Journal of Hepatocellular Carcinoma</i> . <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 1.	1.8	0
62	Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 131.	1.8	18
63	Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2015, 47, 348-349.	0.4	4
64	Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 119-129.	0.6	94
65	The transcription factors Iκ-1 and MZF1 downregulate IGF-1R expression in NPM-ALK+ T-cell lymphoma. <i>Molecular Cancer</i> , 2015, 14, 53.	7.9	19
66	Validation of an IGF-1R scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 21193-21207.	0.8	9
67	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015, 6, 28453-28462.	0.8	9
68	Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	28
69	Reassessing Hepatocellular Carcinoma Staging in a Changing Patient Population. <i>Oncology</i> , 2014, 86, 63-71.	0.9	3
70	Modified cisplatin/interferon $\alpha$ -2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 3334-3342.	2.0	31
71	Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 85, 197-203.	0.9	72
72	Multidisciplinary Management of Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 247-259.	1.8	12

#	ARTICLE	IF	CITATIONS
73	Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial. <i>Oncology</i> , 2012, 82, 67-74.	0.9	87
74	Vâ€œCLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. <i>Cancer</i> , 2011, 117, 2478-2488.	2.0	39
75	Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3892-3899.	0.8	119
76	I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. <i>Oncology</i> , 2011, 80, 373-381.	0.9	34
77	Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 1938-1946.	2.0	283
78	Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States. <i>Hepatology</i> , 2009, 49, 1563-1570.	3.6	141
79	Vascular endothelial growth factor in the management of hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 4895-4906.	2.0	106
80	The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States. <i>Journal of Hepatology</i> , 2009, 50, 334-341.	1.8	73
81	Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Caseâ€œcontrol study. <i>International Journal of Cancer</i> , 2008, 123, 1883-1891.	2.3	73